TY - JOUR T1 - Serum IL-10 and IL-17 are not related to the efficacy of allergen specific immunotherapy in asthma JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P4068 AU - Ioana Agache AU - Mariana Anghel AU - Cristina Ciobanu AU - Liliana Rogozea Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P4068.abstract N2 - Background: Several metaanalyses highlight the efficacy of allergen specific immunotherapy (AIT) in asthma. Markers of immune tolerance were described (IL-10). IL-17 was suggested as a predictor of poor response.Aim: Correlation between serum IL-10 and IL-17 and AIT efficacy parameters.Methods: Following Local Ethics Committee approval and signed informed consent 21 children (11.1±3.38 years) and 19 adults (39.32±10.12 years) with moderate/severe allergic rhinitis and mild asthma (history, FEV1 reversibility ≥12%, FEV1> 80% predicted and positive SPT to common aeroallergens) were administered AIT SC for 3.3±1.4 years (children) and 4.2±1.6 years (adults). Rhinitis and asthma symptom (RSS, ASS), rhinitis medication (RMS), nasal provocation (NPS) scores, asthma exacerbation frequency (AES), inhaled corticosteroid dose (ICS), specific IgE (sIgE) were evaluated at AIT start and end. A full responder was considered if all efficacy parameters decreased by >50%. IL-10 and IL-17 were measured at the end of AIT. T-test and Spearman test.Results: Both in children and in adults RSS, ASS, RMS, AES, ICS, NPS and sIgE decreased significantly (p< 0.0001). Full responders: 62% children, 55% adults.IL-10 did not correlate with any efficacy parameter. IL-17 was weakly negative correlated with the decrease in RMS.Conclusion: AIT showed efficacy in mild allergic asthma. IL-10 and IL-17 could not be related to the efficacy parameters. ER -